The Predictive Value of Alarm Symptoms in Patients With Irritable Bowel Syndrome Based on Rome IV
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03620994|
Recruitment Status : Recruiting
First Posted : August 8, 2018
Last Update Posted : January 11, 2019
|Condition or disease|
|Irritable Bowel Syndrome|
Show Detailed Description
|Study Type :||Observational|
|Estimated Enrollment :||300 participants|
|Official Title:||The Predictive Value of Alarm Symptoms in Patients With Irritable Bowel Syndrome Based on Rome IV|
|Actual Study Start Date :||August 1, 2018|
|Estimated Primary Completion Date :||March 1, 2019|
|Estimated Study Completion Date :||March 1, 2019|
Irritable Bowel Syndrome
All patients who were satisfied with the inclusion criteria and exclusion criteria in the department of the second affiliated hospital of Xi'an JiaoTong University, Xijing Hospital ,Tangdu Hospital or affiliated hospital of Northwest University received investigation. Patients who participate in the study are determined on their own initiative, with full understanding and informedness.
- The incidence of organic bowel diseases [ Time Frame: 6 months ]To collect the results of colonoscopy in patients who meet inclusion criteria, and to calculate the incidence of organic bowel diseases to analyze the predictive value of alarm symptoms.
- The incidence of organic bowel diseases in different subtypes of IBS [ Time Frame: 6 months ]To collect the results of colonoscopy in patients who meet subtypes criteria, and to calculate the incidence of organic bowel diseases to compare the difference in predictive value of alarm symptoms for different subtypes of IBS.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03620994
|Contact: Jinhai Wang, MDemail@example.com|
|Contact: Yang Qianfirstname.lastname@example.org|
|The second affiliated hospital of xi'an jiaotong university||Recruiting|
|Xi'an, Shanxi, China, 710004|
|Contact: Jinhai Wang, MD +86-29-18700932477 email@example.com|
|Contact: Yang Qian +86-29-15091893818 firstname.lastname@example.org|
|Study Director:||Jinhai Wang, MD||The Second Affiliated Hospital of Xi'an Jiaotong University,Xi'an, Shanxi, China|